



## MannKind to Potentially File 2015 10-K Filing Extension

02/26/16

VALENCIA, Calif., Feb. 26, 2016 (GLOBE NEWSWIRE) -- **MannKind Corporation** (Nasdaq:MNKD) (TASE:MNKD) today announced that it anticipates being unable to timely file its Annual Report on Form 10-K for the year ended December 31, 2015 by the filing deadline on February 29, 2016. In such event, the Company anticipates filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission (SEC).

The Company is experiencing delays in completing its analysis of accounting issues resulting from the previously announced termination of the Sanofi License Agreement, and expects that additional time will be needed to complete a detailed review of the impairment of assets as a consequence of the termination.

### About MannKind Corporation

MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at <http://www.mannkindcorp.com> to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

### Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding future filings with the SEC. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the Company's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, developments related to the ongoing analysis of accounting issues arising from the termination of the Sanofi License Agreement. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release except as required by law.

Company Contact:  
Matthew Pfeffer  
Chief Executive Officer  
(661) 775-5300  
[mpfeffer@mannkindcorp.com](mailto:mpfeffer@mannkindcorp.com)